Physician profile
Anne Meier
NPI 1306256839
$15,780.92
in general payments reported to CMS, 2019-2025
70 companies · $4,643 in 2025
The $4,643 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $332 · 2021: $1,003 · 2022: $3,085 · 2023: $2,478 · 2024: $4,121 · 2025: $4,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,145 · Consulting Fee: $1,675 · Honoraria: $1,200 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,145.31 |
| Consulting Fee | $1,675.00 |
| Honoraria | $1,200.00 |
| Education | $222.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,586.12 | 2021-2025 | Calquence, Enhertu, Lynparza |
| Pfizer INC. | $1,632.04 | 2022-2025 | |
| Daiichi Sankyo INC. | $1,427.39 | 2021-2025 | Enhertu, Datroway, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $1,371.02 | 2020-2025 | Opdivo, Reblozyl, Krazati |
| Celgene Corporation | $616.54 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $571.13 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $539.27 | 2021-2025 | Venclexta, Polivy, Phesgo |
| Novartis Pharmaceuticals Corporation | $497.11 | 2021-2025 | |
| Glaxosmithkline, LLC. | $460.99 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $358.19 | 2021-2024 | Libtayo |
| Gilead Sciences, INC. | $339.05 | 2021-2025 | Trodelvy |
| Abbvie INC. | $318.77 | 2021-2025 | |
| Amgen INC. | $266.42 | 2020-2023 | Nplate, Vectibix, Blincyto |
| Foundation Medicine, INC. | $260.24 | 2020-2022 | |
| Genzyme Corporation | $258.74 | 2019-2024 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $233.57 | 2020-2025 | Jakafi |
| Exelixis INC. | $233.22 | 2020-2025 | Cabometyx |
| Eisai INC. | $216.91 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $215.52 | 2024-2025 | Onivyde, Tazverik |
| Astellas Pharma US INC | $185.20 | 2022-2024 | Padcev, Xtandi, Xospata |
| Galvanize Therapeutics, INC | $184.74 | 2025 | Aliya System |
| Seagen INC. | $171.93 | 2021-2023 | Padcev |
| Puma Biotechnology, INC. | $158.85 | 2021-2024 | |
| Sirtex Medical INC | $145.71 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $130.61 | 2021-2023 | Imbruvica, Epkinly |
| Beigene USA, INC. | $127.73 | 2023-2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $122.82 | 2022-2025 | Ultomiris |
| Sobi, INC | $119.50 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $114.51 | 2023-2025 | Monoferric, Cosela |
| Janssen Biotech, INC. | $112.95 | 2021-2025 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $110.08 | 2023-2025 | Alunbrig, Iclusig, Ninlaro |
| Sumitomo Pharma America, INC. | $105.23 | 2024 | Orgovyx |
| Stemline Therapeutics INC. | $96.11 | 2024-2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $92.30 | 2022-2025 | Qinlock, Romvimza |
| Amneal Pharmaceuticals LLC | $81.97 | 2024-2025 | Alymsys, Avastin |
| Jazz Pharmaceuticals INC. | $80.00 | 2023-2025 | |
| Iovance Biotherapeutics, INC. | $76.74 | 2025 | Amtagvi |
| Beone Medicines USA, INC. | $67.63 | 2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $67.06 | 2022-2024 | Tavalisse, Rezlidhia |
| Genmab U.S., INC. | $66.54 | 2024 | Epkinly |
| Lilly USA, LLC | $62.66 | 2021-2024 | Verzenio |
| Recordati_rare_diseases_inc. | $57.33 | 2023-2025 | Enjaymo, Sylvant |
| Blueprint Medicines Corporation | $56.78 | 2023-2024 | Ayvakit |
| Tempus Ai, INC | $54.75 | 2024 | |
| Mirati Therapeutics, INC. | $52.06 | 2023-2024 | Krazati |
| Verity Pharmaceuticals INC. | $50.28 | 2023-2024 | Trelstar |
| Servier Pharmaceuticals LLC | $47.23 | 2024-2025 | |
| Global Blood Therapeutics, INC. | $44.51 | 2022 | |
| Pharmaessentia USA Corporation | $39.43 | 2024-2025 | Besremi |
| Morphosys, US INC. | $39.06 | 2023 | Monjuvi |
| Adc Therapeutics America, INC. | $36.33 | 2022-2025 | |
| Syndax Pharmaceuticals, INC. | $33.56 | 2025 | |
| Geron Corporation | $32.05 | 2025 | Rytelo |
| Array Biopharma INC | $30.74 | 2021-2023 | Lorbrena, Xalkori, Mektovi |
| Sun Pharmaceutical Industries INC. | $29.73 | 2025 | |
| Springworks Therapeutics, INC. | $26.07 | 2025 | Ogsiveo |
| Immunomedics, INC. | $26.05 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.40 | 2023 | |
| Tersera Therapeutics LLC | $24.20 | 2025 | Zoladex |
| Legend Biotech USA INC. | $21.19 | 2024 | |
| Alnylam Pharmaceuticals INC. | $20.50 | 2024 | Givlaari |
| Emd Serono, INC. | $19.19 | 2024 | |
| Agios Pharmaceuticals, INC. | $19.07 | 2023 | Pyrukynd |
| Dova Pharmaceuticals | $18.65 | 2021 | |
| Acrotech Biopharma INC. | $18.35 | 2023 | Beleodaq |
| Janssen Pharmaceuticals, INC | $15.82 | 2022 | |
| Kite Pharma, INC. | $15.73 | 2024 | Yescarta |
| Taiho Oncology, INC. | $14.88 | 2021 | |
| Adaptive Biotechnologies Corporation | $14.72 | 2024 | Clonoseq |
| Clovis Oncology, INC. | $14.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.